Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-074997
Filing Date
2025-08-12
Accepted
2025-08-12 16:31:37
Documents
55
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0252365-10q_citius.htm   iXBRL 10-Q 695302
2 CERTIFICATION ea025236501ex31-1_citius.htm EX-31.1 9185
3 CERTIFICATION ea025236501ex31-2_citius.htm EX-31.2 9225
4 CERTIFICATION ea025236501ex32-1_citius.htm EX-32.1 4132
  Complete submission text file 0001213900-25-074997.txt   4729803

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ctxr-20250630.xsd EX-101.SCH 44570
6 XBRL CALCULATION FILE ctxr-20250630_cal.xml EX-101.CAL 36722
7 XBRL DEFINITION FILE ctxr-20250630_def.xml EX-101.DEF 219221
8 XBRL LABEL FILE ctxr-20250630_lab.xml EX-101.LAB 414933
9 XBRL PRESENTATION FILE ctxr-20250630_pre.xml EX-101.PRE 233450
57 EXTRACTED XBRL INSTANCE DOCUMENT ea0252365-10q_citius_htm.xml XML 458031
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-38174 | Film No.: 251207262
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)